Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2017

View Archived Issues

Praeventix, Temple University identify 5-HT7 antagonists for treating IBD

Alnylam and Sanofi Genzyme initiate ATLAS phase III program for fitusiran

Novel compounds targeting transglutaminase-2 for renal cell carcinoma show promise

Recruitment expanded in phase II breast cancer trial of LiPlaCis

FDA approves Endari for sickle cell disease

Oncology Venture licenses PARP inhibitor from Eisai

Clearances for German phase I trial of IMP-321 in solid tumors

Inotek announces phase II topline results for trabodenoson/latanoprost in glaucoma

Biocartis and A*STAR's ETPL begin development of breast cancer assay

BioTech to pursue critical limb ischemia as first Procell indication based on pilot clinical data

Novan presents new data on SB-204 in adolescents

Oncolys BioPharma enrolls first patient in phase I study of Telomelysin in esophageal cancer

GlaxoSmithKline and Astex Therapeutics describe novel prostaglandin-D2 synthase inhibitors

Immatics initiates phase I ACTolog study

Redx Pharma patents Bruton tyrosine kinase inhibitors

Hangzhou Innogate Pharma presents novel CKD and/or HDAC inhibitors

Inotrem initiates phase II study of Motrem for septic shock

Bardoxolone methyl granted U.S. orphan drug status for Alport syndrome

FDA names entrectinib an orphan drug for NTRK fusion-positive solid tumors

Sirukumab named orphan drug in the U.S. for juvenile idiopathic arthritis

FDA designates tadekinig alfa an orphan treatment for Still's disease

Celgene's avadomide receives U.S. orphan status for hepatocellular carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...